Associated Papers
Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma.
Özoğul E et al.
Blood Cancer Journal, 2024
39313500 (PubMed )
Supplement: 41408_2024_1146_MOESM2_ESM.xlsx › S10
Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma.
López C et al.
Blood Advances, 2024
Mutational landscape of cancer-driver genes across human cancers.
Sinkala M
Scientific Reports, 2023
37550388 (PubMed )
Supplement: 41598_2023_39608_MOESM6_ESM.xlsx › Sheet1
Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis.
Müller H et al.
Cancer Gene Therapy, 2022
Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.
Rodrigues JM et al.
Leukemia & Lymphoma, 2021
34080947 (PubMed )
Supplement: supplement_1.xlsx › Table_S6._Predicted_drivers
Computational analysis of Cyclin D1 gene SNPs and association with breast cancer.
Aftab A et al.
Bioscience Reports, 2021
33438725 (PubMed )
Supplement: BSR-2020-2269_supp.pdf
Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes.
Shin SH et al.
Leukemia & Lymphoma, 2019
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
30736836 (PubMed )
Supplement: 13058_2019_1102_MOESM2_ESM.xlsx › Sheet1
Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.
Annunziata C et al.
International Journal of Cancer, 2018
Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas.
Xu J et al.
Plos One, 2018
A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.
Ben Younes K et al.
Bmc Cancer, 2017
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.
Mohanty A et al.
Oncotarget, 2016
Select a paper to view details